abnormal clotting profile
activated clotting time, 29
anti-Xa agents, 29–30
APTT, 27–8
coagulation screen, principle of, 26
fibrinogen assay, 29
heparin resistance, 29
international normalized ratio, 27
pre-analytical variables, 30
prothrombin time, 26–7
thrombin time, 28–9
activated clotting time (ACT), 29, 50
activated partial thromboplastin time (APTT), 27–8, 60, 83, 193
FFP in children, 229
massive haemorrhage, 94, 98
rFVIIa, 188
acute chest syndrome (ACS), 113, 114
acute haemolytic transfusion reaction (AHTR)
acute immune HTR, 87–8
definition of, 86
HHTR, 88
investigation of, 88
management of, 89
symptoms and signs of, 86–7
acute lung injury (ALI), 90, 130, 166
acute lymphoblastic leukaemia (ALL), 18, 137, 160–1, 236
acute myeloid leukaemia (AML), 18, 19, 137
anaemia
causes of, 107, 108
in critical care
investigation, 4
macrocytosis, 5–8
microcytosis, 5
normocytic, 4–5
pancytopenia, 4
definition of, 3
enzyme deficiencies, 217–18
haemostasis, 94, 97
multiple myeloma, 145
in neonates see neonatal anaemia
prevention of, 121–2
red cell membrane disorders, 216–17
risks of, 108
thrombocytosis, 17
treatment strategies, 119–20
anaemia of chronic disease (AoCD), 4, 31, 35
anticoagulants
HIT, 60–61
reversal and monitoring of
argatroban, 49–50
bivalirudin, 50
dabigatran, 50
fresh frozen plasma, 48
general/supportive measures, 45
heparins and indirect factor Xa inhibitors, 49
rFVIIa and (A)PCC, 48
rivaroxaban and apixaban, 50
vitamin K antagonists, 48–9
anti-embolism stockings (AES), 40, 41
antifibrinolytic drugs, 121, 193
apixaban, 29, 50, 61
APL see acute promyelocytic leukaemia (APL)
aprotilin, 29, 180, 194
APTT see activated partial thromboplastin time (APTT)
argatroban
HIT, 60–61
reversal and monitoring of, 49–50
atypical HUS (aHUS), 66–7
autoimmune haemolytic anaemia (AIHA), 7, 33, 161, 214–15
bilevel positive airway pressure (BIPAP), 168
bivalirudin, 47, 50, 60
blood film
infection, 35–6
platelets, 34–5
preparation of, 31
red cells
macrocytic anaemia, 31, 33–4
microcytic anaemia, 31
normochromic anaemia, 31
polycythaemia, 34
stain for, 31
terminology, 32–3
white cells, 34
Blood Safety and Quality Regulations (BSQR), 77, 80
blood transfusion
anaemia, 108
blood components
clinical use of, 81–3
processing of, 78–80
blood group and compatibility testing, 81
clinical audit, 83–4
clinical special requirements, 225
CMV negative components, 226
HLA-matched platelets, 226
blood transfusion (cont’d)
- hospital transfusion laboratories, 80
- HTCs/HIT, 80
- irradiated cellular components, 225–6
- in neonatal intensive care
  - FFP and cryoprecipitate, 231
  - platelets transfusions, 230–231
  - red cell transfusions, 229–30
- in paediatric critical care
  - cryoprecipitate, 229
  - fresh frozen plasma, 227, 229
  - platelet transfusions, 227
  - red cell transfusion, 226–7
- patient information and consent, 84
- patient management
  - anaemia, 119–22
  - consent for blood transfusion, 119
  - haemorrhage, prevention of, 120–121
  - Jehovah’s Witnesses, 118–19
  - red cell substitutes, 122
- PBM, 80
- and regulatory framework, 77
- risks of, 224–5
- triggers in critical care
  - critically ill children, 109
  - critically ill, non-bleeding patients, 108–9
  - ischaemic heart disease, 109
  - severe sepsis/septic shock, resuscitation in, 109
- bone marrow failure syndromes, 137, 209, 222
- cardiopulmonary bypass (CPB), 14
- ACT, 29
- HIT, 58
- major bleeding, 96
- rFVIIa, 189
- catastrophic antiphospholipid syndrome (CAPS), 55, 67
- catheter-related bloodstream infections (CRBSIs), 132–3
- chemotherapy
  - acute myeloid leukaemia, 159, 160
  - advanced kidney injury, 202
  - CML, 161
  - generic side effects of, 196
  - haemorrhagic cystitis, 141
  - Hodgkin’s lymphoma, 161
  - HVS, 147
  - hyperleukocytosis and leukostasis, 20
  - irradiated blood products, indications for, 201
  - irritants, 200
  - local haemato-oncology units, 200
  - multidisciplinary discussion, 197
  - myeloma infection, 145
  - non-Hodgkin’s lymphoma, 162
  - nursing staff, 200
- progressive breathlessness and rash, 201
- psychosocial support, 197
- renal replacement therapy, 200
- risk of extravasation, 200–201
- selection and dose attenuation, 197–200
- steroids, 197
- supportive care, 200
- venous access, 197
- vesicant drug, 200
- chronic lymphocytic leukaemia (CLL), 18, 34, 160, 161
- chronic myeloid leukaemia (CML)
  - epidemiology of, 160
  - HSCT, 137
  - leukostasis, 19, 34
  - primary thrombocytosis, 17
  - treatment, 161
- chronic myelomonocytic leukaemia (CMML), 17
- CML see chronic myeloid leukaemia (CML)
- coagulopathy
  - acute promyelocytic leukaemia, 20
  - massive haemorrhage see massive haemorrhage
- post-operative bleeding see post-operative bleeding
- cold agglutinin disease (CAD), 7, 214
- congenital bleeding disorder
  - afibrinogenemia/hypofibrinogenemia, 71
  - coagulation factor deficiencies, 72
  - dysfibrinogenemia, 71
- factor VII deficiency, 71–2
- factor XI deficiency, 71
- factor XIII deficiency, 72
- haemophilia A, 70–71
- haemophilia B, 70
- platelet function, disorders of, 72
- thromboprophylaxis, 73
- transfusion-transmitted agents, 72
- von Willebrand disease, 69–70
- continuous positive airway pressure (CPAP), 168
- CRBSIs see catheter-related bloodstream infections (CRBSIs)
- critical care outreach teams (CCOT), 165–6
- cyclophosphamide
  - acute lymphoblastic leukaemia, 160
  - chronic lymphocytic leukaemia, 161
  - multiple myeloma, 163
  - non-Hodgkin’s lymphoma, 162
- secondary TMA, 67
- TTP, 64
- cytomegalovirus (CMV), 9, 13, 77–8, 226
- dabigatran, 50, 61
- damage control resuscitation (DCR), 95, 193
- danaparoid, 49, 60
- delayed haemolytic transfusion reaction (DHTR), 7, 90–91, 115
- desmopressin, 121, 194
- Diamond–Blackfan anaemia, 212
- dilutional thrombocytopenia, 14
- disseminated intravascular coagulation (DIC)
  - activated protein C, 56
  - antithrombin, 56
  - childhood thrombocytopenia, 219
  - clinical features, 52–4
  - definition, 52
  - diagnosis of, 54–5
  - differential diagnosis, 55
  - fibrinogen replacement, 55–6
  - fresh frozen plasma, 55
  - hyperfibrinolysis, 56
  - LMWH, 56
  - pathophysiology of, 52, 53
  - platelet transfusions, 55
  - synthetic protease inhibitors, 56
  - thrombomodulin, 56
  - dysfibrinogenemia, 28, 71, 97
- early goal-directed therapy (EGDT), 109
- enzyme-linked immunosorbent assay (ELISA), 59
- eosinophilia, 21, 22
- erythropoiesis stimulating agents (ESA), 121–2
- essential thrombocytosis (ET), 17
- factor VII deficiency, 48, 71–2
- factor VIII inhibitor bypassing activity (FEIBA), 195
- factor XI deficiency, 71
- factor XIII deficiency, 27, 72
- febrile non-haemolytic transfusion reaction (FNHTR), 86, 89
- fibre-optic bronchoalveolar lavage (FOBAL), 137–8
- fondaparinux, 49, 61
- fresh frozen plasma (FFP)
  - anticoagulants, 48
  - clinical use of, 83
  - coagulation factor deficiencies, 72
  - DIC, 55
  - neonatal transfusion, 231
  - paediatric transfusion, 227
  - processing of, 79–80
- gamma thalassaemia, 211
- gastrointestinal bleeding, 96–7
- G-CSF see granulocyte colony-stimulating factor (G-CSF)
- glucose-6-phosphate dehydrogenase (G6PD)
  - deficiency, 7, 212, 213, 218, 236
- Goodpasture syndrome, 101, 102
Index

graft-versus-host disease (GVHD), 131, 137
granulocyte colony-stimulating factor (G-CSF), 11, 18, 133, 200
Guillain–Barre syndrome, 102

haematological emergencies
chemotherapy-/radiotherapy induced lung injury, 239–40
intrathecal vincristine, inadvertent administration of, 241–2
lymphoma, pericardial involvement, 242
renal failure, high-dose methotrexate, 240–241
SVC syndrome, 238–9
tumour lysis syndrome see tumour lysis syndrome (TLS)

haematological malignancy (HM)
outside intensive care
acutelymphoblastic leukaemia, 160–161
acute myeloid leukaemia, 159–60
chronic lymphocytic leukaemia, 161
chronic myeloid leukaemia, 161
Hodgkin’s lymphoma, 161–2
multiple myeloma, 163
non-Hodgkin’s lymphoma, 162–3

palliative care, in ICU
assessment, 149
care planning, 149
communication, 148, 153
decision-making, 148, 153
food and fluids, 153
hospital-based treatment, 150
intravenous sedatives and opioids, 152
provision, 149
psychological support, 149
psychosocial and spiritual care, 153
symptom management, 149–52, 154
terminal care, 152–3
withholding/withdrawing treatment, 150–151

haematopoietic stem cell transplantation (HSCT)
allogeneic and autologous, 135, 137
complex and toxic procedure, 135
critical care, 142
cytotoxic treatments, 142
definitions and rationale for, 135–6
early and late complications, 138
gastrointestinal and hepatic complications, 140
intensive cytotoxic therapy, 137
late effects of, 142
neurological complications, 141
phases of, 135, 136
relapse of, 141–2
renal and genitourinary complications, 140–141
respiratory complications
chronic lung complications, 140
diffuse alveolar damage, 139
FOBAL, 137–9
idiopathic pneumonia syndrome, 139
infective and noninfective pathology, 137
noninfective pulmonary complications, 140
skin, 141
haemolysis
anaemia, 6–7
bone marrow tissue, 213
causes of, 213–14
clinical features, 213
enzyme deficiency, 217–18
haemoglobinopathies, 218
haptoglobin concentrations, 213
immune-mediated haemolytic anaemia
AIHA, 214–15
HDN, 214
immunoglobulin molecules, 214
intrasplenic haemolysis, 213
microangiopathic haemolytic anaemia, 215–16
neonatal anaemia, 210–212
pathogenesis of, 213
PNH, 215
red cell membrane disorders, 216–17
reticuloendothelial tissues, 213
thalassaemia, 218
haemolysis, elevated liver enzymes and low platelets (HELLP), 65
haemolytic disease of the newborn (HDN), 214, 230
haemolytic uraemic syndrome (HUS), 215
atypical HUS, 66–7
childhood thrombocytopenia, 220
infection-induced (typical) HUS, 65–6
haemophagocytic lymphohistiocytosis (HLH), 4, 220
haemophilia A, 48, 70–71
haemophilia B, 70
heparin-induced thrombocytopenia (HIT), 40
anticoagulation therapies
argatroban, 60–61
dabigatran, 61
fondaparinux, 61
danaparoid, 49
diagnosis, 59–60
DIC, 55
laboratory testing for, 59
pathogenesis/frequency, 58
thrombocytopenia, 59
treatment for, 60
hereditary elliptocytosis (HE), 216–17
hereditary pyropoikilocytosis (HPP), 217
hereditary stomatocytosis, 211, 217
hereditary xerocytosis, 211, 217
HIT see heparin-induced thrombocytopenia (HIT)
HM see haematological malignancy (HM)
Hodgkin’s lymphoma (HL), 161–2, 201
Hospital Transfusion Committees (HTCs), 80
Hospital Transfusion Team (HTT), 80
HSCT see haematopoietic stem cell transplantation (HSCT)

human leukocyte antigen (HLA), 90, 226
hyperesinophilic syndrome (HES), 22
hyperhaemolytic transfusion reaction (HHTR), 87, 88
hyperkalaemia, 235, 238
hyperleukocytosis, 18–20
hyperphosphataemia, 235
hyperviscosity syndrome (HVS), 147
hypocalcaemia, 193, 235, 238
hypofibrinogenaemia, 238
hypothermia, 94, 190, 193

ICU see intensive care unit (ICU)

immune thrombocytopenia (ITP), 14, 220–221
infections
blood film, 35–6
catheter-related infections
diagnosis, 132
Hickman/Groshong lines, 132
management, 133
venous catheters, 132
myeloma, 145
neutropenia, 9
neutropenic fever
aetiology, 125
antimicrobial therapy, 128–30
bacterial pathogens, 128, 129
diagnostic assessment, 128
diagnostic criteria, 125, 128
patient follow up, 130
prevention, 133–4
respiratory tract infection (RTI)
antimicrobial therapy, 131–2
causes, 126–7, 129, 130
diagnostic assessment, 131
haematology patient, 130
IFI, 131
VAP, 130
viral infections, 131
sepsis/septic shock, 130
in severe/specific conditions, 125–7

Intensive Care National Audit and Research Centre (ICNARC) model, 173

intensive care unit (ICU)
admission, prevention of
acute kidney injury, 167
acute respiratory failure, 166
advantages, 169
hypocalcaemia, 146
infusions, 145
MGUS, 145
myeloma bone disease, 145
renal failure, 146
smouldering, 145
spinal cord compression, 145–6
incidence of, 144
Multiple Organ Dysfunction Scores (MODS), 12
myelodysplasia, 5–6
myelodysplastic syndrome (MDS), 17
myeloma bone disease, 145
myeloproliferative neoplasms (MPNs), 17

National Comparative Audit of Blood Transfusion, 83–4
National Institute for Health and Clinical Excellence (NICE), 125
National Patient Safety Agency, 81, 97
necrotizing enterocolitis (NEC), 24, 225
neonatal alloimmune thrombocytopenia (NAIT), 221–2, 231
neonatal anaemia
blood values and impact, 207–8
causes of, 208, 209
haemolysis, 210–212
impaired red cell production, 212
neonatal blood loss, 208, 210
premature infants, 208
red cell production, 207
neonatal intensive care (NICUs)
blood transfusion, 228–9
FFP and cryoprecipitate, 231
platelets, 230–231
red cells, 229–30
thrombocytopenia see thrombocytopenia
neutropenia
differential diagnosis of, 9–10
management of, 10–11
severity of, 9
neutropenic fever
aetiology, 125
antimicrobial therapy, 128–30
bacterial pathogens, 128, 129
diagnostic assessment, 128
diagnostic criteria, 125, 128
non-Hodgkin’s lymphoma (NHL)
aggressive B-cell, 162
indolent B-cell, 162–3
T-cell, 163
non-invasive ventilation (NIV), 114, 139, 168
non-traumatic massive haemorrhage see massive haemorrhage
normochromic anaemia, 31
normocytic anaemia, 4–5, 21, 208
NovoSeven see recombinant activated coagulation factor VII (rFVIIa)
obstetric accidents, 210
oral anticoagulants, 50, 61

paediatric intensive care (PICUs)
  blood transfusion, 228–9
cryoprecipitate, 229
  fresh frozen plasma, 227, 229
platelets, 227
red cells, 226–7
  thrombocytopenia see thrombocytopenia
paroxysmal cold haemoglobinuria (PCH), 6–7
paroxysmal nocturnal haemoglobinuria (PNH), 7, 215
Patient Blood Management (PBM), 80
plasma exchange (PEX)
  centrifugal device, 100
  complications, 103
efficiency of, 101
indications, 102–3
membrane filtration, 100–101
plasmapheresis, 100
treatment plan, 101–2
TTP, 64
plasmapheresis, 49, 100, 215
Plasmodium falciparum, 35–6
pneumonia, 114, 131, 166
  polycythaemia, 34
   causes of, 23
    in critical care, 24–5
    neonatal, 24
    primary, 23
    secondary, 23
    surgery, 24
polycythaemia vera (PV), 17, 23
post-operative bleeding
  activation of factor X (FXa), 192
  anticoagulant effects, 192
  antifibrinolytics, 193
damage control resuscitation, 193
desmopressin (DDAVP), 194
FEIBA, 195
haemostasis overview, 193
lethal triad or bloody vicious cycle, 193
monitoring
  conventional clotting tests, 193
  thromboelastography/
thromboelastometry, 193
rFVIIa, 195
surgical/trans-vascular intervention, 192
thrombin, 192
tissue factor (TF), 192
tissue factor pathway inhibitor (TFPI), 193
thranexamic acid, 193–4
postpartum haemorrhage (PPH), 95, 187, 193
post-thrombotic syndrome (PTS), 42
post-transfusion purpura (PTP), 90, 91
pre-eclamptic toxaemia (PET), 65
primary myelolipobrosis (PMF), 17
prothrombin complex concentrate (PCC), 48, 96
prothrombin time (PT), 26–7, 94, 193
pyrimidine-5'-nucleotidase deficiency, 218
pyruvate kinase deficiency, 212, 218
radiotherapy, 145, 161, 239–40
recombinant activated coagulation factor
  VII (rFVIIa)
   cardiac surgery, 189
economics, 190–191
efficacy and safety of, 187
hazards of, 189
intracerebral haemorrhage, 189
mechanism of action, 187–8
MOH, 96
post-operative bleeding, 195
presentation and dosing, 188
randomized controlled trials (RCTs), 187
transfusion process, 189
trauma, 188–9
vitamin K-dependent coagulation factor, 187
reference intervals
  adult, 244
  paediatric and neonatal, 245–7
respiratory tract infection (RTI)
  antimicrobial therapy, 131–2
  causes, 126–7, 129, 130
diagnostic assessment, 131
haematology patient, 130
IFI, 131
VAP, 130
viral infections, 131
Revised Trauma Score, 190
rFVIIa see recombinant activated coagulation factor VII (rFVIIa)
rituximab
chronic lymphocytic leukaemia, 161
lung injury, 239
NHL, 162
TTP, 64, 220
rivaroxaban, 50, 61
ROTEM®
  advantage of, 181
cell-based model of haemostasis, 181
correlation of rFVIIa with, 181
development, 181
diagnosis of, 182
definition, 182
determination, 182
determination of, 182
diagnosis of, 182
detection, 182
diagnosis, 182
definition, 182
determination of, 182
diagnosis, 182
determination of, 182
diagnosis, 182
determination of, 182
Simplified Acute Physiology Scores (SAPS), 12, 173
sinusoidal obstruction syndrome (SOS), 140
Southeast Asian ovalocytosis, 216, 217
Specialist Advisory Committee on the Safety of Blood, Tissues and Organs
(SaBTO), 77
stroke, 23, 114–15
superior vena cava (SVC) syndrome, 238–9
tenases, 192
thalassaemia, 7, 116, 218
thrombin time (TT), 28–9
thrombocytopenia, 59
blood film, 34–5
characteristics of, 13
in children and neonates
  bone marrow failure syndromes, 222
  bone marrow infiltration, 222
  causes and investigation, 221
disseminated intravascular coagulation, 219
familial thrombocytopenia, 222
haemophagocytic lymphohistiocytosis, 220
HUSTR, 220
immune thrombocytopenia, 220–221
management of, 223
NAIT, 221–2
neonatal autoimmune thrombocytopenia, 222
platelet thresholds, 223
clinical presentation, 12–13
decreased platelet production, 13
definition of, 12
diagnosis, 14
dilution, 14
incidence of, 12
increased platelet aggregation/destruction, 14
Sequential Organ Failure Assessment (SOFA), 56, 173
Serious Adverse Blood Reactions and Events (SABRE), 82
Serious Hazards of Transfusion (SHOT), 82, 224, 225
Shiga toxins (Stx), 65
sickle cell disease (SCD)
  acute chest syndrome, 114
  clinical feature of, 113
  complications of, 115
diagnosis of, 112–13
general anaesthesia, preparation for, 116
ICU patients, transfusion in, 115–16
management of, 113–14
post-operative care, 116
sepsis, 115
stroke, 114–15
Simplified Acute Physiology Scores (SAPS), 12, 173
sinusoidal obstruction syndrome (SOS), 140
Southeast Asian ovalocytosis, 216, 217
Specialist Advisory Committee on the Safety of Blood, Tissues and Organs
(SaBTO), 77
stroke, 23, 114–15
superior vena cava (SVC) syndrome, 238–9
tenases, 192
thalassaemia, 7, 116, 218
thrombin time (TT), 28–9
thrombocytopenia, 59
blood film, 34–5
characteristics of, 13
in children and neonates
  bone marrow failure syndromes, 222
  bone marrow infiltration, 222
  causes and investigation, 221
disseminated intravascular coagulation, 219
familial thrombocytopenia, 222
haemophagocytic lymphohistiocytosis, 220
HUSTR, 220
immune thrombocytopenia, 220–221
management of, 223
NAIT, 221–2
neonatal autoimmune thrombocytopenia, 222
platelet thresholds, 223
clinical presentation, 12–13
decreased platelet production, 13
definition of, 12
diagnosis, 14
dilution, 14
incidence of, 12
increased platelet aggregation/destruction, 14
Sequential Organ Failure Assessment (SOFA), 56, 173
Serious Adverse Blood Reactions and Events (SABRE), 82
Serious Hazards of Transfusion (SHOT), 82, 224, 225
Shiga toxins (Stx), 65
sickle cell disease (SCD)
  acute chest syndrome, 114
  clinical feature of, 113
  complications of, 115
diagnosis of, 112–13
general anaesthesia, preparation for, 116
ICU patients, transfusion in, 115–16
management of, 113–14
post-operative care, 116
sepsis, 115
stroke, 114–15
Simplified Acute Physiology Scores (SAPS), 12, 173
sinusoidal obstruction syndrome (SOS), 140
Southeast Asian ovalocytosis, 216, 217
Specialist Advisory Committee on the Safety of Blood, Tissues and Organs
(SaBTO), 77
stroke, 23, 114–15
superior vena cava (SVC) syndrome, 238–9
tenases, 192
thalassaemia, 7, 116, 218
thrombin time (TT), 28–9
thrombocytopenia, 59
blood film, 34–5
characteristics of, 13
in children and neonates
  bone marrow failure syndromes, 222
  bone marrow infiltration, 222
  causes and investigation, 221
disseminated intravascular coagulation, 219
familial thrombocytopenia, 222
haemophagocytic lymphohistiocytosis, 220
HUSTR, 220
immune thrombocytopenia, 220–221
management of, 223
NAIT, 221–2
neonatal autoimmune thrombocytopenia, 222
platelet thresholds, 223
clinical presentation, 12–13
decreased platelet production, 13
definition of, 12
diagnosis, 14
dilution, 14
incidence of, 12
increased platelet aggregation/destruction, 14
thrombocytopenia (cont’d)
investigations, 15
management of, 15
medical history, 14
platelet sequestration, 14
prognosis, 12
thrombocytosis
blood film, 35
correlation of, 17
in critical care, 17–18
definition of, 16
primary thrombocytosis, 17
reactive thrombocytosis, 16–17
thromboelastogram (TEG)
cell-based model of haemostasis, 181
coaagulation activators, 179, 180
FIBTEM, 181
fresh whole blood, 179
massive haemorrhage, 95
oscillating cup, 179
prediction of transfusion need, 182
speed of clot formation, 179, 180
transfusion algorithms, 182
thromboprophylaxis, 40–41, 73, 147
thrombotic microangiopathies (TMAs)
CAPS, 67
HUS, 65–7
lupus nephritis, 67
malignant hypertension, 67
pregnancy-associated, 65
subtypes of, 63
TAM, 67
TTP see thrombotic thrombocytopenic
purpura (TTP)
thrombotic thrombocytopenic purpura
(TTP)
ADAMTS13 assays, 64–5
clinical features of, 62, 64
filtration-based exchange, 101
immunosuppression, 64
incidence of, 62
laboratory features in, 64
in paediatric and neonatal intensive care,
220
plasma exchange, 64
supportive therapy, 64
vincristine and cyclophosphamide, 64
tissue factor pathway inhibitor (TFPI), 193
TLS see tumour lysis syndrome (TLS)
TMAs see thrombotic microangiopathies
(TMAs)
tranexamic acid, 71, 193–4
transfusion-associated circulatory overload
(TACO), 81, 89–90
transfusion-associated graft-versus-host
disease (TA-GVHD), 91, 225
transfusion reactions
acute reactions
AHTR see acute haemolytic transfusion
reaction (AHTR)
allergy/anaphylaxis, 89
bacterial transmission, 88–9
FNHTR, 89
overview of, 87
TACO, 89–90
TRALL, 90
delayed reactions
DHTR, 90–91
PTP, 91
TA-GVHD, 91
transfusion-related acute lung injury
(TRALI), 86, 90
transfusion transmitted infection, 77–8
transjugular intrahepatic portosystemic
shunt (TIPS), 7
transplant-associated microangiopathy
(TAM), 67
treatment-related mortality (TRM), 136
TTP see thrombotic thrombocytopenic
purpura (TTP)
tumour lysis syndrome (TLS)
acute kidney injury, 167
diagnosis, 235–6
management of, 236–8
twin-to-twin transfusions, 210
unfractionated heparin (UFH), 40, 41, 49, 56
upper gastrointestinal bleeding (UGIB), 96
variant Creutzfeldt–Jakob disease (vCJD), 78
venous thromboembolism (VTE)
asymptomatic and incidental, 43
diagnosis of, 42
epidemiology, 39
interruption of anticoagulation, 43
IVC filters, 42–3
kidney disease, 42
line-related clots and superficial vein
thrombosis, 42
risk factors for, 39–40
thromboprophylaxis, 40–41
trauma, burns and neurosurgical patients,
43
treatment of, 42
ventilator-associated pneumonia (VAP),
130
vincristine, 241
acute lymphoblastic leukaemia, 160
NHL, 162
TTP, 64
viscoelastic haemostatic assay (VHA)
bleeding risk, evaluation of, 181
ROTEM® advantage of, 181
cell-based model of haemostasis, 181
coaagulation activators, 179, 180
prediction of transfusion need, 182
rotating pin, 181
speed of clot formation, 179, 180
transfusion algorithms, 182
TEG®
cell-based model of haemostasis, 181
coaagulation activators, 179, 180
FIBTEM, 181
fresh whole blood, 179
oscillating cup, 179
prediction of transfusion need, 182
rotating pin, 181
speed of clot formation, 179, 180
transfusion algorithms, 182
Wilson’s disease, 7
Zieve’s syndrome, 7, 34